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Drug-induced interstitial lung disease (DILD) is not uncommon and has many clinical patterns, ranging from benign
infiltrates to life-threatening acute respiratory distress syndrome. There are two mechanisms involved in DILD,
which are probably interdependent: one is direct, dose-dependent toxicity and the other is immune-mediated.
Cytotoxic lung injury may result from direct injury to pneumocytes or the alveolar capillary endothelium. Drugs can
induce all types of immunological reactions described by Gell and Coombs; however, most reactions in immune-
mediated DILD may be T cell-mediated.
DILD can be difficult to diagnose; diagnosis is often possible by exclusion alone. Identifying the causative drug that
induces an allergy or cytotoxicity is essential for preventing secondary reactions.
One method to confirm the diagnosis of a drug-induced disease is re-exposure or re-test of the drug. However,
clinicians are reluctant to place patients at further risk of illness, particularly in cases with severe drug-induced
diseases. Assessment of cell-mediated immunity has recently increased, because verifying the presence or absence
of drug-sensitized lymphocytes can aid in confirmation of drug-induced disease. Using peripheral blood samples
from drug-allergic patients, the drug-induced lymphocyte stimulation test (DLST) and the leukocyte migration test
(LMT) can detect the presence of drug-sensitized T cells. However, these tests do not have a definite role in the
diagnosis of DILD. This study explores the potential of these new tests and other similar tests in the diagnosis of
DILD and provides a review of the relevant literature on this topic.
Keywords: DILD, Drug-induced interstitial lung disease, DPT, drug provocation test, DLST, Drug-induced
lymphocyte stimulation test, LMT, leukocyte migration testIntroduction
Several types of drugs can cause drug-induced interstitial
lung disease (DILD). The incidence of DILD for each in-
dividual drug is variable. DILD may be mild to progres-
sive. In its more severe manifestation, DILD may result
in respiratory failure and acute respiratory distress syn-
drome. DILD may develop within the first few days of
treatment or may not until several years after treatment.
DILD is generally described in terms of its clinical/
histopathological features. The mechanisms involved in
drug-induced lung injuries are unclear; therefore, DILD
cannot be classified in terms of pathogenesis.
Diagnosis of DILD generally depends on a definite
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reproduction in any medium, provided the orcausative agent and the development of respiratory signs
and symptoms. The most important for accurate diagno-
sis is the exclusion of other causes of lung damage. Spe-
cific markers, histological findings, and diagnostic
clinical features are generally unremarkable in DILD
[1,2]. Difficulties arise when signs and symptoms de-
velop after the drug is discontinued rather than during
treatment or when no improvement follows discontinu-
ation of the drug. Making a timely and accurate diagno-
sis of DILD is very important to ensure a favorable
outcome [3].
Clinical manifestations and diagnosis of DILD
Clinical manifestations
Laboratory findings and clinical manifestations of DILD,
such as cough, fever, dyspnea, and hypoxemia [1-4], are
non-specific. DILD is indicated when cough, fever, dys-
pnea, and/or pleuritic chest pain are observed in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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absence of evidence of congestive heart failure, infec-
tious disease or malignancy, and when symptoms sub-
side with drug withdrawal. Pulmonary function tests in
the majority of DILD cases may reveal a pattern of re-
strictive abnormality, with decreased values of DLCO.
Discontinuation of the drug is essential, and, in more se-
vere cases, administration of corticosteroids may be of
therapeutic value.
Histology
The histological findings of pulmonary drug reactions
are often non-specific and mimic those of other condi-
tions, such as idiopathic interstitial pneumonia and col-
lagen vascular disease [5]. Almost, all histopathological
subtypes of interstitial lung disease may be observed [3]:
diffuse alveolar damage (DAD), chronic interstitial pneu-
monia [CIP, including non-specific interstitial pneumo-
nia (NSIP), usual interstitial pneumonia (UIP), and
desquamative interstitial pneumonia (DIP)], organizing
pneumonia (OP), eosinophilic pneumonia (EP), hyper-
sensitivity pneumonitis (HP), and granulomatous lung
disease [6-9]. While some drugs, such as minocycline,
methotrexate (MTX), and nitrofurantoin, induce stereo-
typical reactions in the lungs (EP, acute granulomatous
interstitial lung disease, and the cellular type of non-spe-
cific pneumonia, respectively), other drugs, such as
amiodarone and bleomycin, may be associated with
more than one histological pattern [3].
High-resolution computed tomography (HRCT) and
18 F-fluorodeoxyglucose positron emission tomography
(18 F-FDG-PET)
HRCT is currently the best non-invasive method to as-
sess the presence of drug-induced lung disease. The
results of HRCT in DILD are similar to those of ILDs
from other causes or those of idiopathic interstitial
pneumonia. Radiographic manifestations of DILD cor-
respond to those of NSIP, UIP, HP, DAD, cryptogenic
OP (COP)/EP, and diffuse pulmonary hemorrhage.
HRCT may reveal abnormalities in patients with normal
radiographs [8,10,11]. Cleverly et al. reported that
HRCT had an accuracy of only 45% for predicting the
specific histological reaction pattern of DILD [5]. Thus,
HRCT is limited in its ability to predict the histological
patterns in drug-induced lung diseases [5]. HRCT can,
however, be valuable in identifying findings that suggest
an alternative diagnosis and in monitoring responses to
treatments.
Akira et al. reported difuuse or multi-focal ground-
glass opacities with intralobular interstitial thickening as
the predominant findings in anti-neoplastic agent-
induced pneumonitis. Patchy ground-glass opacities with
centrilobular opacities and interlobular septal lines werepredominant radiographic findings in antibiotic agent-
induced pneumonitis [12].
Recently, the use of 18 F-FDG-PET in the diagnosis of
DILD has been reported. FDG uptake was detected at an
extremely early stage when no symptoms or abnormal
findings on HRCT were apparent [13,14]. PET positivity,
however, has no specificity for DILD.
Serum markers
KL-6 has been reported as a sensitive marker for inter-
stitial lung diseases [4,15]. Particular patterns detected
by HRCT, such as DAD and CIP, but not COP/EP or
HP, are associated with increased KL-6 levels in the cir-
culation of patients with DILD [6]. Furthermore, surfac-
tant proteins SP-A and SP-D have been reported as
specific markers of pulmonary fibrosis [16]. Inomata
et al. demonstrated that SP-A, SP-D, and KL-6 levels
were increased in the serum of patients with DILD asso-
ciated with the administration of the epidermal growth
factor receptor-tyrosine kinase inhibitor, gefitinib [17].
Serum ADAM8 (a disintegrin and a metalloproteinase
8) concentrations were significantly elevated in patients
with drug-induced EP, and after a drug provocation test
(DPT), which demonstrated that ADAM8 induction par-
alleled drug-induced eosinophilic lung inflammation
[18].
Bronchoscopy and bronchoalveolar lavage (BAL)
Bronchoscopy can be helpful in determining the pres-
ence of pneumonitis and for the differential diagnosis
of lymphangitic carcinomatosis, vasculitis, alveolar
hemorrhage, or pneumonia from infectious agents.
Most drug-induced immunological reactions, such as
HP and COP/EP, may be excluded if BAL cytology is
normal. The most prominent feature of DILD was a
lymphocytic alveolitis, either pure or associated with
neutrophil and/or eosinophilic alveolitis along with an
imbalance in T lymphocyte phenotype [19]. The most
frequent change observed is lymphocytic alveolitis with
a preponderance of CD8+ cells. In MTX-induced pneu-
monitis, CD4+ cells may also be preferentially increased;
this increase has also been demonstrated with the use of
ampicillin, nitrofurantoin, and sirolimus [20].
Mechanisms involved in DILD
Many different mechanisms may be involved in the initi-
ation and propagation of DILD [21]. Both cytotoxic and
immune mechanisms of action may be involved inde-
pendently or in combination in the tissue expression of
different forms of lung injury [22].
Cytotoxic pulmonary injury
Multiple mechanisms may be responsible for cytotoxic
pulmonary injury due to drugs, including reactive
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tion of metabolites of the lung [26-28], impairment of al-
veolar repair mechanisms [29-31], and release of various
cytokines [23]. Many agents may be toxic to the lungs.
These include cytotoxic drugs, such as bleomycin, MTX,
and cyclophosphamide, and non-cytotoxic drugs, such
as nitrofurantoin, sulfasalazine, and amiodarone [32].
Chemotherapy lung is one representative example of
cytotoxic lung injury. It is a severe type of pulmonary re-
action that develops during or shortly after treatment
with chemotherapeutic agents, such as antibiotics, alkyl-
ating agents, anti-metabolites, nitrosamines, rapamycin
analogs, and podophyllotoxins [4]. Histologically, chemo-
therapy lung corresponds to DAD [1,3]. Concurrent radi-
ation or oxygen therapy increases the risk of developing
chemotherapy lung. Moreover, chemotherapy lung can
sometimes develop because of previously unresolved
chemotherapy- or radiation-induced damage with add-
itional chemotherapy [3].
Mechanisms of cytotoxic pulmonary injuries
The pathogenesis of cytotoxic lung injury may include
direct injury to pneumocytes or the alveolar capillary
endothelium, with subsequent release of cytokines and
recruitment of inflammatory cells. The systemic release
of cytokines induced by chemotherapeutic agents (e.g.,
gemcitabine) may also result in capillary leakage and
pulmonary edema. Early events in lung injury induced
by tricyclic antidepressants may be related to endothelial
damage [21] because of impaired tight junctions
mediated by amitriptyline-induced perturbations in
intracellular calcium [21].
MTX-induced pulmonary toxicity may induce the re-
lease of free oxygen radicals, such as nitric oxide, and
various cytokines, such as IL-1β, TNF-α, and TGF-β.
Kim et al. reported that the p38MAPK signaling pathway
was associated with a pulmonary inflammatory response
[23].
By impairing alveolar repair mechanisms, gefitinib may
potentiate the effects of lung injury [29,30]. Suzuki et al.
have suggested that gefitinib therapy may augment any
underlying pulmonary fibrosis through decrease in epi-
dermal growth factor receptor phosphorylation with co-
incident regenerative epithelial proliferation [31].
The toxic mechanism of amiodarone leads to the dis-
ruption of the lysosomal membranes of molecules
through protein C activation and the subsequent release
of toxic oxygen radicals, which may induce activation of
caspase pathways and lead to apoptosis of lung epithelial
cells [24]. An additional mechanism reduces deactivation
of toxic metabolites of the drug [26,27].
Pulmonary toxicity may also be caused by the gener-
ation of free oxygen radicals by mitomycin C, nitrofur-
antoin, and bleomycin. These drug-induced ROSgenerate substances such as H2O2, O2-, and OH [21]. In
vivo and in vitro studies showed bleomycine, a cancer
chemotherapeutic agent, to be the cause of pulmonary
toxicity, which was mediated, at least partly, by a bleo-
mycin-iron complex, generating toxic O2-derived species
within the lung [25]. Particular susceptibility to bleo-
mycin toxicity in the lung may depend on the fact that
bleomycin is preferentially distributed in lung tissue and
that the lung is relatively deficient in the hydrolase en-
zyme that detoxifies bleomycin [28].
Nitrofurantoin and bleomycin share the ability to gen-
erate O2 radicals and to cause lung damage. The reason
that these drugs affect the lungs as their predominant
site of toxicity remains unclear. One possibility is the
rate of gas exchange and high oxygen load in the lungs,
which enables damage due to these drugs [21].
Diagnosis of cytotoxic pulmonary injury
Drug-induced pulmonary toxicity can be difficult to
diagnose because cancer patients are usually adminis-
tered multiple anti-neoplastic agents; thus, identifying
the causative agent becomes difficult. Unfortunately, no
single diagnostic test or tissue biopsy is currently avail-
able that can definitively confirm a diagnosis of chemo-
therapy-associated lung disease [33].
Currently, in vitro drug challenge is not a readily avail-
able or clinically validated diagnostic assay for cytotoxic
lung injury. Reactive drug metabolites are believed to
play a role in many drug reactions. Differences in the
capacity of cells to detoxify the reactive metabolites of
drugs are important determinants in drug toxicity reac-
tions, and these differences could be used as the basis of
a diagnostic assay. Microsomes are a source of oxidative
enzymes, primarily cytochrome P450 (CYP). Cell viabil-
ity can be determined after incubating microsomes with
PBMCs and the suspected drug in the presence or ab-
sence of a microsomal activating system. This assay has
not been used for the diagnosis of cytotoxic lung injury.
However, this approach may enhance our understanding
of selected drugs that cause DILD, paving the way for
development of clinically useful assays [34,35].
Immune-mediated pulmonary injuries
General pathogenesis of drug allergies
Exposure to a particular drug can induce immune reac-
tions in a minority of individuals. Although most have
not yet been identified, several factors may control this
process: the chemical structure of the molecule (anti-
genic drug determinants); genetic factors including poly-
morphisms of genes that encode drugs that metabolize
enzymes and immune responses; environmental factors
(stress, concurrent infection, and pollution); and the na-
ture of drug exposure (dose, duration, frequency, and
route of administration) [36].
˙ ˙ ˙
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Our knowledge regarding human immune responses to
drugs remains limited. Drug hypersensitivity and other
immune reactions are frequently categorized according
to Gell and Coombs classification, which includes four
categories that reflect distinct immune mechanisms. This
variety explains the heterogeneous clinical presentations
that can occur [37]. All these reactions are T cell-regulated,
but the effector functions are primarily antibody-mediated
factor functions (I-III). Most of the reactions in immune-
mediated DILD may be T cell-mediated. DILD associated
with a type III reaction was investigated in a case report.
Schatz et al. reported a case of pneumonitis characterized
by an eosinophilic interstitial infiltrate with evidence of im-
munofluorescent staining and immune complex-mediated
activation of the classic complement pathway [38].
(b) drug recognition
With regard to the role of T cells in drug hypersensitivity,
a question arises: how do T cells recognize drugs? [34].
(b)-(i) hapten concept
The recognition of small molecules like drugs by B and
T cells is usually explained by the hapten concept. In
their native states, most drugs are not immunogenic.
Many drugs have low molecular weights (<1000 kDa)
and must be covalently bound to high-molecular-weight
carrier proteins to become effective immunogens
[36,39]. A hapten may directly bind to an immunogenic
peptide presented by a major histocompatibility complex
molecule.
A drug that is not chemically reactive per se may be-
come reactive on metabolism [39]. Once formed, these
reactive metabolites may cause cytotoxicity and/or be-
come covalently bound to cellular proteins [40]. The
ability to form immunogenic complexes and mount an
immune response to these complexes differs among
individuals [39].
(b)-(ii) p-i concept
Pichler et al. elaborated another possibility; namely, a
pharmacological interaction between drugs and immune
receptors (p-i concept) [36]. They found that chemically
inert drugs, which could not covalently bind to peptides
or proteins, could directly activate certain T cells if they
happened to bear T cell receptors that could interact
with the drug. According to the “p-i” model, which is
metabolism- and processing-independent, the struc-
tural features of a drug elicit an immunological re-
sponse [36].
(b)-(iii) danger model
One of the major functions of the adaptive immune sys-
tem is to distinguish “self” from “non-self.” If theimmune system encounters self proteins, it will result in
tolerance. In contrast, encounter with non-self or foreign
proteins leads to an immune response.
Matzinger proposed an alternative explanation, labeled
the Danger Model, of the generation of immune
responses [40]. According to Matzinger, the activation of
dendritic cells can be induced by endogenous danger
signals, such as - release by tissues undergoing stress,
damage, or abnormal death, and by exogenous danger
signals elaborated by pathogens. Certain drugs may
cause cell injury and act as immunologic triggers.
A schematic representation of drug-induced pulmon-
ary effects and toxicity is provided in Figure 1.
Diagnostic tests in drug hypersensitivity reactions
In vitro diagnostic tests are useful in cases of clinical un-
certainty to confirm a clinical diagnosis. To determine
which test is optimal for confirming the clinical diagno-
sis of an adverse drug reaction, an appreciation of the
pathophysiological mechanism(s) responsible for the ad-
verse reaction is critical [34]. Potentially useful diagnostic
tests in DILD include the drug lymphocyte stimulation
test (DLST), LMT [41], and flow cytometry.
Mechanisms and diagnosis of immune-mediated DILD
Lungs provide a barrier to illness in which the immune
system is chronically activated to provide optimal host
defense. This constant, low-level activation provides a
milieu that may facilitates pro-inflammatory signals and
subsequent immune system responses.
Minocycline-induced pneumonia (MIP) is generally
manifested as EP. A central role for T lymphocytes in
the immunologic reaction to MIP was suggested by Gil-
lon et al., who identified lymphocyte-mediated specific
cytotoxicity against minocycline-bearing alveolar macro-
phages in vitro [42]. Their findings, however, do not ex-
plain the presence of pulmonary eosinophilia, which is a
characteristic feature of MIP. Thus, further investiga-
tions are needed to elucidate the pathophysiology of
MIP. Three different mechanisms of amiodarone
induced lung disease have been suggested: a direct toxic
effect, an immune-mediated mechanism, the angiotensin
enzyme system activation [9]. From the immunological
perspective, Kuruma et al. reported that the Th1/Th2
balance may influence amiodarone metabolism and may
be a powerful indicator of amiodarone-induced subclin-
ical lung toxicity [43].
(a) diagnosis of immune-mediated DILD
Causative drugs are determined from the history of drug
exposure and any response to withdrawal of an impli-
cated drug. An in vitro test such as the DLST can only
detect the presence of sensitization, but cannot predict
whether the sensitization will lead to symptoms [44].
Figure 1 Schematic representation of drug-induced pulmonary effects and toxicity including hypothetical pathogenenic mechanisms
involved.
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sensitization to a drug, but also the clinical manifesta-
tions induced by this sensitization [44]. The utility of
skin testing in DILD, however, has not been reported.
(a)-(i) in vitro tests for DILD
DLST and LMT are bioassays that help to confirm the
presence of drug-sensitized lymphocytes. The DLST
verifies the growth of sensitized lymphocytes after a drug
is used for antigen stimulation, while the LMT identifies
the cytokines or chemokines produced by sensitized
lymphocytes after a drug is used for antigen stimulation
[45].
The DLST is the most commonly used in vitro test for
detecting the causative drug in cases of drug allergy. The
causes of drug allergies determined using the DLST have
been extensively reported in cases of drug eruption
[44,46,47]. Laboratory-based in vitro methods, such as
the DLST, have numerous advantages, including abso-
lute safety, ability to assess T cell responses to multipledrugs simultaneously, and absence of risk of developing
additional drug allergies [44]. This technique measures
the uptake of a DNA precursor (tritiated [3H] thymi-
dine) after lymphocytes have been exposed to an antigen
in vitro. This test is associated with blast formation by
lymphocytes [44].
The LMT demonstrates the presence of sensitized
lymphocytes when granulocytes, either alone or mixed
with normal lymphocytes, exhibit migration inhibition
when cultured at optimal drug concentrations. Saito
et al. reported that the LMT had a higher positive re-
sponse rate than the DLST for several hypersensitivity
symptoms, such as skin eruptions and hepatic injury
[45].
While DLST has been widely used in the diagnosis of
DILD in Japan, this is not the case in other countries.
Compelling data as to the sensitivity and specificity of
the DLST for DILD is currently lacking. A cell-mediated
hypersensitivity reaction on DLST is the basis for diag-
nosis of gold-induced pneumonia (GIP). Tomioka and
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tive DLST in their diagnostic scheme for GIP [39]. How-
ever, GIP is rarely a clinical problem at the present time.
Studies on the use of DLST in DIP are far from well
controlled. Based on data that compared the results of
the DLST and provocation tests for patients with DILD,
DLST contributed little in detecting the causative agents
in these patients [48,49].
DLST is believed to be insensitive to MIP. Toyoshima
et al. reported the results of DLST for minocycline in six
patients; in all cases, the results were negative [50]. In
addition, suppressive effects of minocycline on T cell
proliferation have been described [51,52].
For MTX and Kampo (Japanese herbal) drugs, the
results of DLST tend to be overestimated. Many reports
have provided evidence that the uptake of 3H thymidine
into lymphocytes in the presence of MTX may be
explained by the upregulated incorporation of thymidine
from the extracellular space following the depletion of
the intracellular thymidine pool caused by MTX. In one
study, MTX created an early block in the cell cycle with-
out reducing the cellular uptake of 3H-thymidine [53].
Hoffman also found a discrepancy between the forma-
tion of blast-like cells and high thymidine uptake in
MTX-treated, mitogen-stimulated lymphocytes [54].
Hirata et al. showed that DLST using MTX was inad-
equate in confirming MTX-induced DILD [55].
Kampo drugs are generally contaminated with non-
specific mitogens from plants. Mantani et al. reported
positive DLST results for Kampo drugs in 85.7% of en-
rolled patients not taking any Kampo medicines [56]. In
addition, several studies reported discrepancies between
DLST findings and results of provocation drug tests in
Kampo drugs [7,18,48,49].
Leukocyte migration inhibition factor production has
also been observed in well-established cases of hypersen-
sitivity pneumonitis, such as that due to beryllium
[42,57]. Various reports have drawn attention to the
positive results of this test in cases of DILD due to dif-
ferent drugs, such as minocycline, amiodarone, propran-
olol, nitrofurantoin, gold salts, MTX, and paclitaxel
[41,57-61]. However, the number of samples used in
these reports were small.
CD69 upregulation on T cells has been reported as an
in vitro marker for delayed-type drug hypersensitivity
reactions [62]. Compared with other early T cell activa-
tion markers, such as CD71 or CD25, CD69 appeared to
be most suitable, as it was rapidly upregulated and
showed the greatest difference from baseline values [63].
CD69 upregulation was shown to be drug-specific and
not an inherent property of cells derived from patients.
It did not occur in unstimulated cultures or in drug-
stimulated PBMCs from non-allergic donors. Cells from
drug-allergic subjects reacted only to the causative drug,but not to any other tested drugs [63]. This assay has not
been used for the diagnosis of DILD. However, this ap-
proach may enhance our understanding of selected drugs
that cause DILD.
(a)-(ii) drug provocation tests (DPT)
Rechallenge of patients with DILD is generally consid-
ered unethical as the pulmonary damage caused by
DILD is largely irreversible, and re-challenge increases
the risk to the patient. Re-test of drugs has been safely
performed in some patients, although a fatality was
reported following a re-test with MTX in one case [64].
Several investigators have conducted re-tests with mino-
cycline to establish an accurate diagnosis [65] with no
reported morbidity. Similar findings have been reported
for EP induced by other drugs, such as sulfalazine [3],
amoxicillin [7], and nimesulide [66].
Recently, Yasui et al [48]. proposed a DPT method for
mild DILD. DPT was performed in 58cases, 41 of which
showed positive results. This test was initiated by admin-
istering the lowest dosage of the suspected causal drug
that could achieve a response, and then gradually in-
creasing the dose at daily intervals until a normal daily
dose was reached or symptoms occurred. This DPT
protocol was deemed useful according to the criteria
provided by Yasui et al [48,49]. Their diagnostic criteria
for DIP included a 1°C increase in body temperature and
one or more of the following an increase in the alveolar-
arterial difference in oxygen tension (A-aDO2) of
>10 mmHg; an increase >20% in white blood cell count;
and positive conversion of C-reactive protein [48,49].
Pulmonary inflammation and fibrosis
Monoclonal antibodies have emerged as a new class of
agents that can cause DILD. The number of cases of
ILD triggered by anti-TNF-α agents is increasing. TNF-α
has both pro- and anti-fibrotic effects. TNF-α can pro-
mote pulmonary tissue repair, eliminating inflammatory
cells by inducing their apoptosis [52,67,68]. Increase in
the local releases of inflammatory cell-derived proteolytic
enzymes may enhance the potential pulmonary toxicity of
MTX, which may then be potentiated by an anti- TNF-α
agent, resulting in impaired apoptosis of infiltrating inflam-
matory cells [67]. Anti- TNF-α therapy may also result in
systemic and/or pulmonary shifts towards anti-inflamma-
tory cytokines, such as TGF-β1, thus contributing to a pro-
fibrotic state [67], which would explain the exacerbation
seen in pulmonary fibrosis.
Rituximab, an anti-CD20 antibody, has been reported to
induce a heterogeneous spectrum of lung disease. The re-
lease of cytokines, such as TNF-α, IFN-α, IL-6, and IL-8,
has been postulated as the mechanism responsible. Other
possible mechanisms of induction include comple-
ment activation or indirect cytotoxic T lymphocyte
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induced by dendritic cells that, in turn, are stimulated
by cell-derived peptides resulting from rituximab-
induced cell destruction. These activated CTL’s may
cause vascular and alveolar damage thereby, initiating
lung injury [14,69].
Drug interactions and cross-reactivity
Drug interactions that cause ILD have not been reported
except in one case report by McFadden et al., who
reported a case of “gold-naproxen pneumonitis.” They
hypothesized that naproxen interfered with the ability to
restrain the immune response to gold, which resulted in
clinical pneumonitis that resolved only when both na-
proxen and gold were discontinued. This was the first
suggestion of a “drug interaction” that could cause lung
injury [70].
Cross-reactivity has not been documented with drugs
that cause ILD [3].
Host susceptibility in DILD
The mechanisms by which some patients exhibit high
susceptibility while others appears to be resistant remain
largely unknown. However, several possibilities have
been suggested.
The human leukocyte antigen (HLA) complex plays a
central role in presenting antigens for T cell recognition.
In certain immune based disorders, the pattern of HLA
class II allele presentation confers both resistance and
susceptibility to disease onset. Rheumatoid arthritis (RA)
patients who tested positive for HLA-B40 had a 10.5-
fold relative risk and those positive for Dw1 had a 6.2-
fold relative risk of developing gold-induced pneumon-
itis as compared with RA patients without these antigens
[71].
Both genetic and intrinsic factors can affect the dispos-
ition of certain drugs (absorption, distribution, metabol-
ism, and excretion). Several different xenobiotic-
metabolizing CYP and conjugation enzymes have been
shown to be present in the lung [72-74].
CYP single nucleotide polymorphisms are among the
key factors known to cause variations in drug responses
among individuals [75]. Wijnen et al. indicated that
DILD might be attributed to a reduced metabolic cap-
acity because of CYP enzymes. They indicated that vari-
ous CYP genotypes presented a substantial susceptibility
risk factor for the development of DILD [76]. Therefore,
genotyping prior to drug prescription may be clinically
useful for predicting and preventing DILD.
Conclusion
This review has focused on the mechanistic aspects of
DILD, describing several different mechanisms that may
be involved in the initiation and propagation of DILD.With better clarification of these processes, the predic-
tion of DILD should be possible in the not too distant
future. In addition, the validation of previously devel-
oped techniques and the development of new tests will
contribute enormously to progress in the diagnostic
evaluation of DILD.
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